914604-52-7

Upstream product

• 96-41-3 Cyclopentanol 
• 2935-35-5 (S)-2-phenylglycine 
• 104-15-4 toluene-4-sulfonic acid 

Downstream Products

• 914604-84-5 (S)-(2-nitro-benzylamino)-phenyl-acetic acid cyclopentyl ester 
• 914604-51-6 (S)-(4-nitro-benzylamino)-phenyl-acetic acid cyclopentyl ester 
• 1023699-81-1 cyclopentyl (2S)-({4-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]benzyl}amino)(phenyl)acetate 
• 914382-70-0 (S)-[(3-amino-benzyl)-tert-butoxycarbonyl-amino]-phenyl-acetic acid cyclopentyl ester 
• 914382-69-7 (S)-[tert-butoxycarbonyl-(3-nitro-benzyl)-amino]-phenyl-acetic acid cyclopentyl ester 
• 914604-86-7 (S)-[(2-amino-benzyl)-tert-butoxycarbonyl-amino]-phenyl-acetic acid cyclopentyl ester 
• 914604-53-8 (S)-[tert-butoxycarbonyl-(4-nitro-benzyl)-amino]-phenyl-acetic acid cyclopentyl ester 
• 914604-54-9 (S)-[(4-amino-benzyl)-tert-butoxycarbonyl-amino]-phenyl-acetic acid cylopentyl ester 
• 914604-85-6 (S)-[tert-butoxycarbonyl-(2-nitro-benzyl)-amino]-phenyl-acetic acid cyclopentyl ester 
• 914606-40-9 (S)-[tert-butoxycarbonyl-(3-{[2-(1-isobutoxy-ethoxycarbamoyl)-benzo[b]-thiophen-6-ylmethyl]-amino}-benzyl)-amino]-phenyl-acetic acid cyclopentyl ester 
• 1351815-73-0 cyclopentyl (2S)-[(4-{[{[2,4-bis(benzyloxy)-5-(prop-1-en-2-yl)phenyl]carbonyl}(methyl)amino]methyl}benzyl)amino](phenyl)ethanoate 
• 1351815-69-4 cyclopentyl (2S)-[(3-{[{[2,4-bis(benzyloxy)-5-(prop-1-en-2-yl)phenyl]carbonyl}(methyl)amino]methyl}benzyl)amino](phenyl)ethanoate 
• 1151804-32-8 cyclopentyl (2S)-[(2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-yl]phenyl}ethyl)amino](phenyl)acetate 
• 914605-55-3 (S)-[3-(3-nitro-benzyl)-ureido]-phenyl-acetic acid cyclopentyl ester 

Relevant academic research and scientific papers

INHIBITORS OF HSP90

The invention provides a compound which is (a) a pyrrolopyrimidine derivative of formula (I) or a tautomer thereof, or (b) a pharmaceutically acceptable salt, N-oxide, hydrate or solvate thereof: Formula (I) wherein R1, R2, R3/

P38 MAP KINASE INHIBITORS

Compounds of formula (I) are inhibitors of p38 MAP kinase, and are therefore of utility in the treatment of, inter alia, inflammatory conditions including rheumatoid arthritis and COPD: formula (I) wherein: G is -N= or -CH=; D is an optionally substituted divalent mono- or bi-cyclic aryl or heteroaryl radical having 5 - 13 ring members; R6 is hydrogen or optionally substituted C1-C3 alkyl; P represents hydrogen and U represents a radical of formula (IA); or U represents hydrogen and P represents a radical of formula -A-(CH2)z-X1-L1 -Y-NH-CHR1R2 wherein A represents an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5 - 13 ring members; z, Y, L1, and X1 are as defined in the specification; R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; and R2 is the side chain of a natural or non-natural alpha amino acid.

HDAC INHIBITORS

Compounds of formula (I) inhibit HDAC activity, wherein A, B and D independently represent =C- or =N-; W is a divalent radical -CH=CH- or CH2CH2-; R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non-natural alpha amino acid; z is 0 or 1; and Y, L1, and X1 are as defined in the claims.

PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER

Compounds of formula (I) are inhibitors of Polo-like kinases (PLKs), and are useful, inter alia, in the treatment of proliferative diseases: wherein R1 is hydrogen, or a (C1C6)alkyl, (C2-C6)alkenyl, (

HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE

Compounds of formula (I), and salts, N-oxides, hydrates and solvates thereof are histone deacetylase inhibitors and are useful in the treatment of cell proliferative diseases, including cancers: wherein Q, V and W independently represent -N= or -C=; B is

INHIBITORS OF P38 MITOGEN-ACTIVATED PROTEIN KINASE

Compounds of formula (I) are inhibitors of p38 MAP kinase activity, and are useful in the treatment of, inter alia, inflammatory and autoimmune disease formula (I): wherein R3, R4, R5 and R6 are each independently hydrogen or halogen; M and P are independently -N= or -CH=; Z is (a) a radical of formula R1R2CHNH-Y-L1-X1-(CH2)Z-, wherein R1R2CHNH- is an N-linked amino acid or amino acid ester group as defined in the description, and -Y-L1-X1-(CH2)Z- is a linker radical as defined in the description.

IKK-β SERINE-THREONINE PROTEIN KINASE INHIBITORS

Compounds of formula (IA) or (IB) are inhibitors of IkB kinase (IKK) activity, and are useful in the treatment of autoimmune and inflammatory diseases: Formula (A) and (B) wherein R7 is hydrogen or optionally substituted (C1-C6)alkyl; ring A is an optionally substituted aryl or heteroaryl ring of 5-13 ring atoms; Z is (a) a radical of formula R1R2CHNH-Y-L1-X1-(CH2)Z- wherein: z is 0 or 1; R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non- natural alpha amino acid; Y is a bond, -C(=O)-, -S(=O)2-, -C(=O)O-, -C(=O)NR3-, - C(=S)-NR3, -C(=NH)-NR3 or -S(=O)2NR3- wherein R3 is hydrogen or optionally substituted C1-C6 alkyl; L1 is a divalent linker radical of formula -(Alk1)m(Q)n(Alk2)p- wherein m, n, p, Q, AIk1 and AIk2 are as defined in the claims.

p38 MAP KINASE INHIBITORS

Compounds of formula (I) are inhibitors of p38 MAP kinase, and are therefore of utility in the treatment of, inter alia, inflammatory conditions including rheumatoid arthritis and COPD: (I), wherein: G is -N= or -CH=; D is an optionally substituted divale

THIAZOLE DERIVATIVES AS INHIBITORS OF P13 KINASE

Compounds of formula (I) are inhibitors of P13 kinase activity, and useful in treatment of, inter alia, autoimmune, inflammatory and proliferative diseases: wherein: s is 0 or 1; U is hydrogen or halogen; X is -(C=O), an optionally substituted divalent ph